摘要
Abstract
Objective To evaluate the safety and efficacy of Everolimus ( ERI ) combined with different doses of Calcineurin Inhibitors ( CNI ) for renal transplantation recipients in immunosuppression. Methods The datas were searched Embase,PubMed,Science Citation Index,Cochrane Library,CNKI,Wanfang Data,Chinese Biomedical Database disc,VIP information,the randomized controlled trials ( RCTs ) based on the inclusion criteria by using different dose of CNI combined with ERI after renal transplantation,then we assessed method-ological quality,extracted data and the studies were meta-analyzed by using RevMan 5. 0 software. Results 3 RCTs were eligible. The Meta-analysis indicated that:after renal transplantation,compared with CNI high-dose group,the biopsy-proven acute rejection and mortality of CNI low-dose group were not statistically significant(P > 0. 05);glomerular filtration rate,serum creatinine levels and cre-atinine clearance rate were statistically significant(P < 0. 05). Risks of graft loss were related with the type of CNIs. The adverse reac-tions were not statistically significant(P > 0. 05). Conclusion Based on the evidence,the low-dose CNI combined with ERI improved kidney function after renal transplantation.关键词
肾移植/依维莫司/钙调磷酸酶抑制剂/Meta分析Key words
renal transplantation/Everlimus/calcineurin inhibitor/Meta-analysis分类
医药卫生
